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To the Editor: Takahashi et al.1 have recently described the effect of nicotinamide for controlling 
hyperphosphatemia in dialysis patients. However, Rottembourg et al.2 reported thrombocytopenia in the same 
setting. We have started a prospective, open-label trial to study the efficiency and safety of nicotinamide in our 
hemodialysis patients with resistant hyperphosphatemia. Unlike Takahashi, we did not stop other phosphate 
binders. Six patients have already been included. Two patients were intolerant to sevelamer and thus only treated 
with calcium carbonate. The other four patients received a combined therapy. Five patients developed diarrhea 
during the study. In two of them, it was so important that nicotinamide had to be stopped. After discontinuing 
nicotinamide, diarrhea disappeared. In the three other patients, diarrhea improved with decreasing the dose of 
nicotinamide. The diarrhea started at a mean dose of 1050 ± 447 mg. We observed a significant decrease in 
phosphatemia while on treatment (from 85 ± 8.7 to 54 ± 12.1mg/l; P = 0.0048 for the repeated measure analysis 
of variance), but no effect on platelet count (from 260.167 ± 40.435 to 281.167 ± 51.503; P = 0.33). 
Diarrhea induced by high doses of nicotinamide is not described in non-renal failure population.3 However, in 
Takahashi's study, 7.8% of the patients developed such an adverse effect.1 In our population, diarrhea induced by 
nicotinamide might also be related to the simultaneous use of calcium carbonate and/or sevelamer. If 
nicotinamide proves to be useful in the management of hyperphosphatemia, more studies are needed to evaluate 
its safety at high doses. 
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